Celldex Therapeutics (NASDAQ: CLDX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Celldex Therapeutics Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Celldex Therapeutics Company Info
A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease.
News & Analysis
The short answer: They were impressive.
The company announced a public stock offering.
Investors liked Celldex's early stage clinical results.
Not at its present valuation, it's not.
The biotech reported interim results from a phase 1b study.
Here's why shares of these drugmakers seem unstoppable this year.
Here's what pushed up shares of the highest-flying healthcare stocks.
The market is reacting to large stock purchases from inside and outside the company.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
CLDX earnings call for the period ending June 30, 2019.
CLDX earnings call for the period ending December 31, 2018.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.